SCHEMBL12724325

SCHEMBL12724325

COc1ccc2nc(N3CCOCC3)ccc2c1Br

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.52
▸ HPGD P15428 5/20 0.52
▸ KDM4E B2RXH2 5/20 0.52
▸ GAA P10253 4/20 0.52
▸ NPC1 O15118 3/20 0.52
▸ RAB9A P51151 3/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ GLA P06280 1/20 0.52
▸ CYP1A2 P05177 3/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ CYP3A4 P08684 2/20 0.44
▸ CNR2 P34972 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ CLK4 Q9HAZ1 1/20 0.44
▸ TSHR P16473 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12701772 0.83 ALDH1A1 (0.56) ALDH1A1HPGDKDM4EGAANPC1
SCHEMBL4659260 0.80 NPC1 (0.45) ALDH1A1HPGDKDM4EGAANPC1
SCHEMBL1134096 0.80 NPC1 (0.48) ALDH1A1HPGDKDM4EGAANPC1
SCHEMBL4658361 0.73 KDM4E (0.49) ALDH1A1HPGDKDM4EGAANPC1
SCHEMBL12701060 0.73 KDM4E (0.54) ALDH1A1HPGDKDM4EGAANPC1
SCHEMBL15300930 0.72 OGA (0.54) ALDH1A1HPGDKDM4EGAANPC1
SCHEMBL1336745 0.70 ADORA1 (0.42) ALDH1A1GAAMEN1KMT2ATSHR
SCHEMBL1134024 0.69 CYP19A1 (0.40) ALDH1A1NPC1MAPT
SCHEMBL30784355 0.69 PIM1 (0.50) ALDH1A1HPGDGAASMN1; SMN2MEN1
SCHEMBL17086891 0.69 CYP19A1 (0.45) ALDH1A1TDP1ERN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431704-B2 Quinoline or isoquinoline substituted P2X7 antagonists JANSSEN PHARMACEUTICA NV (BE) 2013-04-30 — — US disclosed
US-20110092481-A1 QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS JANSSEN PHARMACEUTICA NV 2011-04-21 — — US disclosed
WO-2009132000-A1 QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2009-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092481-A1 QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS P2RX7, P2RX1, P2RX3 ALDH1A1 2008/4885HPGD 934/4885KDM4E 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback